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Introduction
It is estimated that 10% of the worldwide 
disease burden is attributable to inadequate 
standards in drinking water, sanitation, and 
hygiene (Prüss-Üstün et al. 2008). One of the 
largest threats to human health worldwide, 
particularly in rural and developing areas, 
is the presence of high levels of inorganic 
arsenic (iAs) in drinking water. Although 
the World Health Organization (WHO) 
has recommended that the levels of iAs in 
drinking water should not exceed 10 ppb 
(WHO 2011), > 100 million people world-
wide are believed to be exposed to levels in 
drinking water that exceed this limit (Uddin 
and Huda 2011). Much of this exposure is 
attributable to the use of iAs-contaminated 
groundwater as a source of drinking water. 
Although groundwater may be contaminated 
with iAs due to anthropogenic activities, it is 
most often contaminated due to geological 
leaching (Garelick et al. 2008). Rural areas 
and developing countries are often particu-
larly impacted based on their reliance on 
groundwater as a source of drinking water. In 
terms of affected populations, the impact of 
this exposure is perhaps most evident in areas 
of Southeast Asia, including Bangladesh and 
India (Mukherjee et al. 2006; Sen and Biswas 
2013). For instance, it has been estimated that 
35–77 million of the 125 million inhabitants 
of Bangladesh may have been exposed to iAs 
levels in drinking water that exceed the WHO 
standard (Karagas 2010; Smith et al. 2000). In 
addition to the situation in Southeast Asia, it is 
becoming increasingly clear that iAs contami-
nation of groundwater and surface waters is 
a worldwide problem. Inorganic As concen-
trations in groundwater have been detected 
around the globe at levels that greatly exceed 
the WHO standard, suggesting many more 
populations may be at risk (Ravenscroft et al. 
2009). Although countries such as the United 
States have adopted the WHO standard for 
limiting iAs exposure via municipally supplied 
water, many people in these countries, 
perhaps numbering in the millions, may still 
be exposed to relatively high levels of iAs via 
use of unregulated private wells supplied with 
groundwater (George et al. 2006; Sanders et al. 
2012). Exposure for populations who gener-
ally have more moderate iAs exposure from 
drinking water than Southeast Asian popula-
tions also may occur through the consumption 
of certain foods such as rice and rice products 
[Cottingham et al. 2013; Davis et al. 2012; 
European Food Safety Authority (EFSA) 
2009]. This is of particular concern to vulner-
able subpopulations such as infants and young 
children who have increased susceptibility to 
toxicants and may consume relatively large 
proportions of rice-containing products 
compared with adults.
Numerous and varied health effects 
are attributed to iAs exposure in human 
populations, such as adverse pregnancy/
birth outcomes, increased morbidity and 
mortality in infants and children, cognitive 
impairments in children, and the develop-
ment of noncommunicable diseases in adults 
including cardiovascular disease, peripheral 
vascular disease, chronic respiratory disease, 
and various cancers (Mazumder et al. 2005; 
Parvez et al. 2013; Rahman A et al. 2007, 
2011; Rahman MM et al. 2009; Raqib et al. 
2009; Smith and Steinmaus 2009; Wasserman 
et al. 2004, 2007). The carcinogenic impacts 
of chronic iAs exposure are among the best-
characterized and most intensely studied effects 
of iAs. These effects have been reported at a 
wide variety of iAs concentrations including 
relatively low concentrations observed in the 
United States (Garcia-Esquinas et al. 2013; 
Gilbert-Diamond et al. 2013). Inorganic As 
is classified as a known human carcinogen 
that targets multiple organs including 
the skin, lung, urinary bladder, and liver 
(International Agency for Research on Cancer 
2012; National Research Council 2001). 
Elucidating the molecular mechanisms that 
link iAs exposure to disease has proven to 
be a daunting task given the complexity of 
disease states and multiplicity of factors that 
likely influence disease development. Several 
mechanisms have been implicated in the devel-
opment of iAs-associated cancers, including 
the generation of oxidative stress, interference 
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Background: Millions of individuals worldwide, particularly those living in rural and developing 
areas, are exposed to harmful levels of inorganic arsenic (iAs) in their drinking water. Inorganic As 
exposure during key developmental periods is associated with a variety of adverse health effects, 
including those that are evident in adulthood. There is considerable interest in identifying the 
molecular mechanisms that relate early-life iAs exposure to the development of these latent diseases, 
particularly in relationship to cancer.
oBjectives: This work summarizes research on the molecular mechanisms that underlie the 
increased risk of cancer development in adulthood that is associated with early-life iAs exposure.
discussion: Epigenetic reprogramming that imparts functional changes in gene expression, the 
development of cancer stem cells, and immunomodulation are plausible underlying mechanisms by 
which early-life iAs exposure elicits latent carcinogenic effects.
conclusions: Evidence is mounting that relates early-life iAs exposure and cancer development 
later in life. Future research should include animal studies that address mechanistic hypotheses and 
studies of human populations that integrate early-life exposure, molecular alterations, and latent 
disease outcomes.
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with DNA repair, alterations in cellular 
signaling, and alterations to the genome and 
epigenome. No single mechanism has emerged 
as a key event, and it is likely that iAs exerts 
 carcinogenic effects via multiple mechanisms.
In the present commentary we summarize 
the current state of knowledge of the rela-
tionship between early-life iAs exposure and 
altered disease risk. In particular, we high-
light research needs that would best elucidate 
the molecular mechanisms linking early-life 
exposure to iAs and cancer development 
later in life. Epigenetic reprogramming has 
been a major research focus in this area, and 
we highlight this as well as two additional 
and likely interacting mechanisms that may 
contribute to carcinogenic effects associ-
ated with early-life iAs exposure, namely the 
development of cancer stem cells (CSCs) and 
perturbed immune function.
Early-Life Inorganic Arsenic 
Exposure: Evidence for the 
Development of Cancers in 
Animals Models and Human 
Populations
In both exposed human populations and 
experimental animals, exposure to iAs during 
critical developmental periods has been 
shown to be sufficient to alter the risk of 
developing adverse health effects much later 
in life (reviewed by Farzan et al. 2013a). For 
instance, iAs has been shown to cause delayed 
carcinogenic effects in several strains of mice 
when they are exposed briefly during the 
prenatal period. This effect was first observed 
in C3H mice, in which offspring born to 
pregnant females exposed briefly to high 
doses of sodium arsenite [NaAs2O3; iAs(III)] 
in drinking water [42.5 or 85 ppm arsenic 
during gestational days (GD) 8–18] resulted 
in increased incidence and/or multiplicity of 
tumors in multiple organs in both female and 
male adult offspring (Waalkes et al. 2003, 
2004b). Sex-specific effects were observed, 
including a pronounced dose–response effect 
in the incidence and multiplicity of hepato-
cellular carcinoma (HCC), a major form of 
cancer associated with chronic iAs exposure 
in humans, in male offspring (Waalkes et al. 
2003). Exposure to iAs(III) prenatally as 
described above followed by postnatal appli-
cation of tumor-promoting agents was also 
found to produce cancers, tumors, and/or 
proliferative lesions in some organs, and to 
have initiating effects in other organs in several 
strains of mice (Tokar et al. 2010a; Waalkes 
et al. 2004c, 2006a, 2006b, 2008). Prenatal 
iAs exposure is also associated with acceler-
ated/exacerbated atherosclerosis in apolipo-
protein A-knockout (ApoE–/–) mice, a mouse 
strain used to study atherosclerotic disease. In 
this model, male offspring born to pregnant 
ApoE–/– mice administered 85 ppm iAs(III) 
from GD8 to birth (GD20) is associated with 
evidence of increased atherosclerotic disease 
in male offspring 10 and 16 weeks after birth 
compared to controls (Srivastava et al. 2007). 
Other effects have also been reported at signifi-
cantly lower doses, such as cognitive impair-
ments in adult C57B16/J mice that were born 
to dams exposed to 100 μg/L iAs in drinking 
water from 1 week before conception until 
birth (Cronican et al. 2013).
In epidemiologic studies with an ecological 
design, a defined period of iAs exposure in 
northern Chile revealed several similarities to 
the mouse studies cited above, namely that 
early-life exposure to iAs was associated with a 
variety of latent health impacts, some of which 
are sex dependent. For instance, young adults 
(age 30–49 years) who experienced prenatal 
and/or childhood exposure via high levels of 
iAs in municipally supplied drinking water 
(average level, 860 μg/L) in the Antofagasta 
region of northern Chile between 1958 and 
1970 had increased mortality from both 
cancerous and noncancerous effects, including 
chronic renal disease, chronic lung disease, 
acute myocardial infarction, and cancers of 
the urinary bladder, larynx, kidney, lung, and 
liver (Smith et al. 2006, 2012; Steinmaus 
et al. 2014; Yuan et al. 2007, 2010). Although 
ecologic studies may be limited by a lack of 
individual exposure and outcome data, these 
findings have been supported by a case–control 
study in the same part of Chile with individual 
data linking the early life exposures with 
increased cancer risk in adults (Steinmaus et al. 
2014). Taken together, these results highlight 
the sensitivity of early-life periods to the effects 
of iAs, notably at very high levels of exposure, 
and a major research focus in recent years has 
been to understand the molecular alterations 
that link exposure during these periods to 
delayed effects, particularly cancers, later in life.
As discussed in more detail below, analyses 
of tissue from target organs in C3H and 
ApoE–/– mice that were prenatally exposed to 
iAs indicated that this altered disease suscep-
tibility was associated with persistent changes 
in the expression and epigenetic landscape of 
genes implicated in disease development (Liu 
et al. 2004; States et al. 2012; Waalkes et al. 
2004a; Xie et al. 2007). These observations are 
consistent with theories that suggest perma-
nent alterations or “reprogramming” of the 
epigenome is a critical link between toxicant 
exposure in early life and altered disease risk 
later in life (Bollati and Baccarelli 2010; Jirtle 
and Skinner 2007). The epigenome, widely 
considered to include DNA methylation, 
histone post-translational modifications, and 
microRNAs (miRNAs), plays a critical role 
in the regulation of gene expression; there-
fore, epigenetic reprogramming by toxicants 
may alter the susceptibility to adverse health 
outcomes by causing persistent changes 
in expression patterns of genes involved in 
disease development. Epigenetic reprogram-
ming has been a major focus of research efforts 
that have set out to elucidate the molecular 
mechanisms that underlie the link between 
early-life iAs exposure and altered disease risk.
Molecular Mechanisms 
Underlying Latent Carcinogenic 
Effects Associated with 
Early-Life Arsenic Exposure
Epigenetic reprogramming/alterations in gene 
expression. There are several indications in 
transplacental exposure models that iAs may 
alter disease risk in adulthood via epigenetic 
reprograming and altered gene expres-
sion. For instance, liver tissue isolated from 
newborn male mice exposed to hepatocar-
cinogenic doses of iAs in utero had alterations 
in GC-rich regions throughout the genome 
and altered expression of genes implicated in 
liver tumorigenesis (Waalkes et al. 2004a; Xie 
et al. 2007). The expression profiles of similar 
disease- associated genes were also observed in 
HCCs and peritumorous tissue in transpla-
centally exposed adult male mice (Liu et al. 
2004; Waalkes et al. 2004a; Xie et al. 2007). 
Of particular interest was the increased expres-
sion of estrogen receptor alpha (Er-α), which 
was concurrent with hypomethylation of 
several regions of DNA in the Er-α promoter 
(Waalkes et al. 2004a). This is of potential 
significance because there is often an inverse 
relationship between promoter methylation 
status and transcriptional competency. In the 
ApoE–/– athero sclerosis model, brief prenatal 
exposure to 49 ppm iAs(III) in maternal 
drinking water was shown to alter the tran-
scriptional profiles in the livers of male mice 
that were evident at postnatal day (PND) 1 
and PND 70; interestingly, the altered mRNA 
and miRNA profiles differed between these 
two time points, which is consistent with 
reprogramming of gene expression profiles 
in the liver (States et al. 2012). Although the 
mouse transplacental carcinogenesis models 
support an associative relationship between 
alterations in DNA methylation and the 
altered expression of key genes, it is unknown 
whether this relationship is causal, and the 
mechanisms that underlie the altered DNA 
methylation patterns are unknown. The 
molecular events that cause the reprogram-
ming of gene expression in the mouse athero-
sclerosis model are also unknown and must 
be explored. In addition, the impact of other 
epigenetic alterations in the developmental 
origins of iAs-based disease has been relatively 
unexplored in animal models. One study 
revealed an association in C57B16/J mice 
between transplacental exposure to 100 μg/L 
iAs in maternal drinking water, alterations in 
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global H3K9 acetylation patterns, and cogni-
tive impairments in adulthood, which is of 
potential significance because changes in 
histone acetylation patterns have been reported 
in cognitive insufficiencies (Cronican et al. 
2013). These studies also highlight that epigen-
etic alterations may be a mechanism by which 
iAs may cause a variety of adverse health effects 
throughout the lifetime of an individual, many 
of which are likely unrecognized. Chronic 
respiratory symptoms have been reported 
to be increased in children following early-
life exposure to iAs in Bangladesh, although 
without evidence of reduced lung function 
(Smith et al. 2013). A recent study reported 
that early-life exposure to iAs was associated 
with reduced lung function in children (Recio-
Vega et al. 2015). The results of these studies 
need to be confirmed, but they underscore that 
long latency periods are not necessarily associ-
ated with all adverse health effects associated 
with early-life iAs exposure.
A major area of focus in recent years has 
been the examination of alterations in gene 
expression and epigenetic alterations, including 
DNA methylation and miRNAs, that are asso-
ciated with early-life iAs exposure in humans. 
Many of these analyses have focused on 
alterations observed in cord blood leukocytes. 
Related to prenatal iAs exposure and tran-
scriptional change, a transcriptomics approach 
identified 447 iAs-responsive genes in cord 
blood leukocytes in newborns from Thailand 
(n = 32; range of maternal toenail arsenic 
levels in unexposed subjects, 0.10–0.38 μg/g; 
or exposed subjects, 0.50–68.63 μg/g) (Fry 
et al. 2007). Most of these genes had increased 
expression levels associated with iAs exposure 
and were enriched for roles in immune and 
inflammatory response, stress response, and 
cancer/tumorigenesis. Related to epigenetic 
regulation of the transcriptional response, in 
Mexican newborns (n = 40; range of iAs in 
maternal drinking water = < 1 to 236 μg/L), 
12 miRNAs and 334 mRNAs were identified 
that were correlated with arsenic levels of total 
urinary arsenic in maternal urine (range of 
U-tAs, 6.2–319.7 μg/L) (Rager et al. 2014). 
Functional analyses indicated the modulated 
miRNAs are known to be regulators of cellular 
responses such as inflammation and diseases 
with known links to iAs exposure including 
cancer and diabetes mellitus. Nine of the 
modulated miRNAs were predicted to regulate 
the expression levels of approximately 20% of 
the U-tAs-associated mRNAs, providing an 
indication that miRNAs regulate, at least to 
some extent, the transcriptional response to 
prenatal iAs exposure.
Several analyses have examined iAs-associ-
ated perturbations of cord blood proteins. For 
instance, the level of several proinflammatory 
cytokines in the cord blood of Bangladeshi 
newborns (n = 130; median U-tAs = 66 μg/L), 
namely interleukin 1 beta (IL-1β), inter-
leukin 8 (IL-8), tumor necrosis factor (TNF), 
and interferon gamma (INF-γ), had U-shaped 
curves across quartiles of maternal U-tAs at 
gestational week 30 (GW30) (Ahmed et al. 
2011). Using a proteomic strategy, Bailey 
et al. (2014) identified a total of 111 maternal 
U-tAs–associated cord blood proteins 
in Mexican newborns (n = 50; range of 
U-tAs, 6.2–319.7 μg/L). These proteins were 
enriched in functions related to immune/
inflammatory response and cellular develop-
ment/proliferation, and the majority were 
predicted to be regulated by TNF, a protein 
that is implicated in the development of 
several adverse health effects associated with 
iAs exposure. Most newborns had a positive 
association between the levels of proteins and 
U-tAs, which was consistent with a proinflam-
matory response. However, this relationship 
was inverted in some newborns, underscoring 
an interindividual response to prenatal iAs 
exposure that may impact susceptibility to 
adverse health outcomes. The basis for these 
interindividual differences remains unknown 
but may be related to iAs metabolism. These 
studies reveal that at the mRNA, miRNA, and 
protein levels, genes with similar functions 
such as immune response are altered in the 
cord blood of prenatally exposed newborns 
across several populations. As discussed below, 
alterations in immune function are impli-
cated in a variety of adverse health impacts 
associated with early-life iAs exposure. Still, a 
precise mechanistic relationship between these 
alterations and adverse health impacts remains 
unknown. Furthermore, although leukocytes 
have roles in immune function, the relevance 
of altered gene expression profiles in leukocytes 
to the development/susceptibility of adverse 
effects in other target tissues is unclear.
Studies that have examined epigenetic 
effects associated with early-life iAs exposure 
have focused on changes in DNA methyla-
tion at both the gene-specific level and global 
level (Intarasunanont et al. 2012; Kile et al. 
2012; Pilsner et al. 2012). Gene-specific 
changes may be significant because they 
impart functional changes in gene expres-
sion levels. Global changes in methylation 
status of the genome may also be important 
because such changes may be associated with 
genetic instability. More recent studies have 
used genome-wide approaches to identify 
associations between iAs exposure and the 
methylation status of individual CpG sites, 
the primary target of DNA methylation in 
humans (Broberg et al. 2014; Kile et al. 2014; 
Koestler et al. 2013; Rojas et al. 2015).
Sex-dependent relationships have been 
observed between the global DNA methylation 
status of cord blood leukocytes of Bangladeshi 
newborns (n = 101; range of iAs in maternal 
drinking water, 0.01–66.1 μg/L), and prenatal 
iAs exposure, in which this relationship was 
positive in newborn males and negative in 
newborn females (Pilsner et al. 2012). In 
Thailand (n = 71; range of iAs in maternal 
drinking water, 0.18–8.38 μg/L), the meth-
ylation status of long interspersed element 1 
(LINE-1) elements was used as an indicator 
of changes in global DNA methylation levels 
(Intarasunanont et al. 2012). No associations 
between LINE-1 methylation and indicators 
of prenatal iAs exposure were observed, but 
this study did identify a positive relationship 
between in utero arsenic exposure and DNA 
methylation of the tumor protein 53 (TP53) 
promoter. In iAs-exposed mother–child 
pairs in Bangladesh (n = 113; range of iAs in 
maternal drinking water, < 1 to 230 μg/L), the 
relationship between iAs exposure and DNA 
methylation patterns of LINE-1 and the TP53 
and cyclin-dependent kinase inhibitor 2A 
(CDKN2A/p16) promoters were examined in 
maternal and umbilical cord leukocytes (Kile 
et al. 2012). Similar DNA methylation patterns 
were observed in mothers and newborns, which 
included a positive association between maternal 
U-tAs and LINE-1 methylation and some CpG 
sites within the p16 promoter. Evidence of a 
nonlinear dose–response relationship was also 
observed, as the most effects were observed in 
the middle tertiles of exposure. These results 
raise the possibility that epigenetic effects may 
be observed at relatively moderate levels of 
exposure, and that dose–response relationships 
may be complex, thus underscoring the need for 
follow-up studies.
Several genome-wide analyses have identi-
fied changes in cord blood DNA methylation 
profiles associated with prenatal iAs exposure. 
One study identified changes observed in 
New Hampshire newborns exposed to rela-
tively low levels of iAs in utero (average iAs in 
maternal drinking water, 1.2 μg/L; average 
U-tAs, 4.1 μg/L) (Koestler et al. 2013). Several 
DNA regions were identified in which there 
was a relationship between DNA methyla-
tion levels and maternal U-tAs, but no overall 
change in the global DNA methyla tion status 
was observed. Most of these differentially meth-
ylated regions were found to be within CpG 
islands, the CpG-rich areas of euchromatin 
known to epigenetically regulate gene expression 
(Koestler et al. 2013). In Bangladesh (n = 127; 
median maternal U-tAs at GW30, 89 μg/L), 
an inverse correlation was observed between 
maternal U-tAs and the DNA methylation 
status of cord blood CpG sites predominantly 
in boys, and pathway-level analyses of differ-
entially methylated genes revealed an overrep-
resentation of functions associated with cancer 
development in boys compared with girls 
(Broberg et al. 2014). Another genome-wide 
analysis of cord blood of prenatally exposed 
Bangladeshi newborns identified differential 
methylation within CpG regions of cord blood 
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leukocytes in relationship to prenatal arsenic 
exposure. Importantly, this analysis identified 
a positive association of DNA methylation of 
CpG regions within 71 genes and levels with 
iAs in maternal drinking water after adjusting 
for U-tAs–associated shifts in leukocyte popula-
tions, thus highlighting that alterations in DNA 
methylation profiles must be corrected for shifts 
in leukocyte populations that may occur due 
to iAs exposure (Kile et al. 2014). To date, one 
genome-wide study has investigated the rela-
tionship between changes in DNA methyla-
tion and gene expression in prenatally exposed 
newborns (Rojas et al. 2015). In this Mexican 
population (n = 38; arsenic in maternal drinking 
water, 1–236 μg/L; mean U-tAs, 73.87 μg/L), 
the methylation status of CpG sites from 
2,919 genes isolated from newborn cord blood 
was found to be associated with prenatal iAs 
exposure. DNA methylation changes within the 
first exon and within 200 bp of the transcription 
start site yielded the most significant association 
with gene expression profiles. In addition, a set 
of 7 target genes including growth-associated 
and diabetes- associated genes such as the 
imprinted gene KCNQ1 (potassium voltage–
gated channel, KQT-like subfamily, member 1) 
were differentially methylated, differentially 
expressed, and associated with birth outcomes/
measures in relationship to prenatal arsenic 
exposure (Rojas et al. 2015). This research iden-
tified a commonality at the sequence level of 
the differentially methylated genes related to 
transcriptional factor binding. This transcrip-
tion factor occupancy was proposed as a basis 
for gene-specific DNA methylation patterning 
that could underlie responses to iAs and 
other  environmental contaminants (Sanders 
et al. 2014).
Taken together, these studies reveal several 
important findings: that iAs-associated altera-
tions in DNA methylation patterns are observed 
across populations that are exposed to varying 
levels of iAs, and that complex dose–response 
relationships have been observed. Effects may 
be sex-dependent and mother–child pairs have 
similar alteration patterns, which may have 
relevance to sex-dependent and interindividual 
susceptibility to iAs-associated disease. The rele-
vance of these alterations to long-term disease 
susceptibility and, to a large extent, changes 
in gene expression patterns at the mRNA or 
protein level remains unknown and must be 
explored. As with gene expression patterns, 
the relevance of changes in DNA methylation 
patterns in blood leukocytes to disease risk in 
various target organs is also unknown.
Cancer stem cells. In vitro and in vivo 
evidence has indicated that the emergence of 
CSCs after prenatal iAs exposure may play 
important roles in the development of some 
iAs-associated cancers, including those associ-
ated with prenatal iAs exposure. CSCs have 
altered stem cell (SC) functions but retain some 
characteristics that are key for their survival 
and later development into cancers such as 
self-renewal, quiescence, ability to differentiate, 
and conditional mortality (Tokar et al. 2011). 
In the iAs-exposed fetus, CSCs are believed 
to arise from normal SCs or slightly differen-
tiated SC progeny and remain quiescent in 
target organs until ultimately transforming 
into malignant cells (Tokar et al. 2011). 
Interestingly, evidence suggests that CSC over-
abundance is a characteristic not of all carcino-
gens but of at least some iAs-associated cancers; 
for instance, the malignant transformation of 
the prostate epithelial cell line RWPE-1 by iAs 
exposure in vitro resulted in an overabundance 
of CSCs compared with RWPE-1 cells trans-
formed by cadmium or N-methyl-N-nitrosurea 
(Tokar et al. 2010b). Arsenic-transformed 
malignant epithelial cells have also been shown 
to “recruit” normal SCs into a CSC phenotype 
(Xu et al. 2012), which may help explain the 
CSC overabundance often observed in iAs-
induced tumors and iAs-transformed cell lines 
(Tokar et al. 2010b).
The triggers that end the quiescent state 
to produce cancers are unknown but may 
include the effects of continued exposure to 
iAs during the postnatal period or postnatal 
exposure to other chemicals. For instance, an 
overabundance of CSCs was observed in the 
highly aggressive squamous-cell carcinomas 
(SSCs) that developed in Tg.AC mice after 
prenatally exposure to carcinogenic doses 
(42.5 and 85 ppm) of iAs(III) followed by 
postnatal application of 2 μg/0.1 mL acetone 
12-O-tetradecanoyl phorbol-13-acetate to the 
skin for 36 weeks (Waalkes et al. 2008). There 
is evidence that aberrant gene expression is a 
key, early event in the development of CSCs. 
For instance, the fetal skin of Tg.AC mice 
that were prenatally exposed to iAs demon-
strated increased expression of several genes 
associated with SC/carcinogenesis functions 
including the oncogene v-Ha-ras, a cell surface 
marker of keratinocyte SCs and cancer skin 
cells (CD34), and a gene involved in kera-
tinocyte SC renewal, namely ras-related C3 
botulinum toxin substrate 1 (Rac1). Similar 
to results observed in fetal skin, an examina-
tion of the highly aggressive SCCs that devel-
oped in Tg.AC mice after prenatal arsenic 
exposure and postnatal TPA exposure also 
revealed high expression of v-Ha-ras and the 
CSC markers CD34 and Rac compared with 
tumors that arose after TPA treatment alone 
(Waalkes et al. 2008). A comparison of the 
tumors arising from these two treatment groups 
showed increased expression levels of the pro-
growth gene Cd1 and decreased expression of 
tumor suppressor p16 in the aggressive SCCs 
in the iAs arsenic/TPA group (Waalkes et al. 
2008). These data demonstrate a relationship 
between gene expression and the acquisition 
of malignant phenotype. The mechanisms that 
link iAs exposure and changes in gene expres-
sion patterns of these key genes in CSCs remain 
understudied and must be addressed. No 
alterations were shown in the DNA methyla-
tion status of the v-Ha-ras promoter concurrent 
with increased v-Ha-ras expression (Waalkes 
et al. 2008), even though v-Ha-ras expression 
has been shown to be controlled by promoter 
DNA methylation status in Tg.AC mice 
(Cannon et al. 1998). These results underscore 
that both epigenetic and non-epigenetic regula-
tory mechanisms must be explored as potential 
mechanisms of iAs-induced changes in gene 
expression, and that it must be taken into 
account that experimental outcomes depend 
on a variety of factors including differences in 
experimental design and methods used.
Immunomodulatory effects. There is consid-
erable evidence from in vitro studies, a range 
of animal models, and chronically/prenatally 
exposed human populations that iAs has various 
immunomodulatory effects (reviewed by 
Dangleben et al. 2013). Interestingly, the effects 
of iAs on the immune system are complex and 
seemingly divergent as they include evidence of 
both immunosuppression and inflammation, 
and markers of both effects have been observed 
simultaneously in exposed populations (Soto-
Peña et al. 2006). At the molecular level, there 
are several indications that the immune system 
is a major target of iAs toxicity as immune 
response is a predominant function associated 
with perturbed mRNAs, miRNAs, and proteins 
in the cord blood of iAs-exposed newborns from 
Mexico or Thailand (Ahmed et al. 2011; Bailey 
et al. 2014; Fry et al. 2007; Rager et al. 2014). 
As discussed below, the immunosuppressive and 
proinflammatory effects may contribute not 
only to long-term health effects of iAs such as 
cancers but to adverse short-term health effects 
associated with early-life iAs exposure as well.
Immunosuppression is a significant health 
concern because of the major roles of the 
immune system in functions such as healing 
wounds and providing defense against micro-
bial infections and cancers (Reuter et al. 2010; 
Vesely et al. 2011). Indicators of immunosup-
pression that have been observed in prenatally 
exposed infants in Bangladesh include higher 
mortality, reduced thymic indices, reduced 
T-cell function, and higher morbidity rates 
from pneumonia and diarrhea (Nadeau et al. 
2014; Rahman A et al. 2010, 2011; Raqib 
et al. 2009). There is evidence that more 
moderate levels of prenatal exposure can 
also affect immune response, as prenatal iAs 
exposure was associated with total number of 
infections requiring physician visit/ prescription 
medication in infants in New Hampshire 
(Farzan et al. 2013b). It is currently unknown 
whether immunosuppressive effects associated 
with prenatal iAs exposure persist into later life. 
If these effects are sustained, they will likely 
increase the susceptibility to infections and 
Bailey et al.
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chronic diseases including cancers that have 
been associated with iAs exposure (DeWitt 
et al. 2012; Vega et al. 2009).
There are also indicators of proinflamma-
tory effects in prenatally exposed infants such 
as the increased expression of proinflamma-
tory genes at the mRNA and protein levels 
in newborn cord blood, evidence of oxida-
tive damage in the placenta, and increased 
expression of proinflammatory proteins in 
the placenta such as IL1-β, TNF, and IFN-γ 
(Ahmed et al. 2011; Bailey et al. 2014; Fry 
et al. 2007; Nadeau et al. 2014). As a potent 
producer of reactive oxygen species (ROS), 
iAs can stimulate proinflammatory effects that 
not only cause macromolecule damage but 
also activate ROS-sensitive signaling pathways 
implicated in disease development such as 
those that involve mitogen-activated protein 
kinases (MAPKs) and the transcription factor 
nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) (Sesti et al. 2012). 
Of note, inflammation is associated with 
several diseases associated with iAs exposure 
including adverse birth/pregnancy outcomes, 
and a sustained inflammatory state is impli-
cated in the development of several chronic 
diseases associated with iAs exposure including 
cancers, diabetes mellitus, atherosclerosis, and 
liver fibrosis (Challis et al. 2009; Cosentino 
and Egidy Assenza 2004; Iredale 2007; Libby 
et al. 2002; Vahter 2007; Valko et al. 2006). 
Therefore, it is likely that susceptibility to 
early- and later-life disease development may 
be linked in part to the complex impacts of 
prenatal iAs exposure on the immune system.
Conclusions
Studies in both animal models and human 
populations have revealed that exposure to iAs 
during key developmental periods is associated 
with the development of latent health effects 
including cancers. Because of the latent nature 
of many of the effects of iAs exposure, the 
actual extent of the impact of such exposure is 
likely underestimated. Although the research 
relating early-life exposure to iAs and the devel-
opment of long-term health effects continues 
to advance, many knowledge gaps remain. 
Detailed molecular analyses in animal models 
that employ gene knockouts or chemical inhi-
bition of targeted pathways are required to 
elucidate the precise mechanisms linking iAs 
exposure and adverse health effects. In addition, 
relationships must be identified between early-
life iAs exposure, molecular alterations, and 
short-term and long-term health impacts. In 
many cases, it is unknown whether molecular 
alterations associated with iAs exposure are 
persistent. Thus future research should help to 
differentiate between adaptive versus adverse 
alterations and may establish biomarkers of 
exposure and disease susceptibility. It is also 
clear that some disease-specific mechanisms 
such as CSCs exist, but that others such as 
epigenetic reprogramming and alterations in 
immune function may contribute to the devel-
opment of numerous adverse health impacts. 
Studies must also continue to examine effects 
observed across a wide range of iAs exposure 
levels in different populations across the globe, 
which will help inform dose–response relation-
ships, sex-dependent impacts, and cofactors 
contributing to disease susceptibility. Taken 
together, the studies described here underscore 
that there are likely multiple mechanisms that 
contribute to the development of latent diseases 
associated with early-life iAs exposure.
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